EIRGENIX RECEIVED THE ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM JAPAN
EirGenix is committed to the development of biosimilar drugs and CDMO (Contract Development and Manufacturing) service. We officially received the accreditation certificate of foreign drug manufacturer approved by the Ministry of Health, Labour, and Welfare in Japan.
This certificate of foreign drug manufacturer is classified as "Biological products", and its effective time is from October 31, 2017 to October 30, 2022, a period of five years.
Within the validity period in the future, EirGenix can bring our biological products manufactured in Taiwanese facility to Japan for sale. It is expected to substantially attract international pharmaceutical OEM orders, then Eirgenix's CDMO business will grow and go further into the international market.